MOTS-c Employer Coverage and ICHRA Navigation: A Woman's Guide to Lowering Your Cost

What Is MOTS-c and Why Are Women Asking About It?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondria-derived peptide encoded in the 12S ribosomal RNA gene of mitochondrial DNA. It is 16 amino acids long and acts on skeletal muscle and adipose tissue to improve insulin sensitivity and support mitochondrial function. The original characterization was published in Cell Metabolism in 2015, where Lee et al. Demonstrated that MOTS-c regulated metabolic homeostasis and prevented diet-induced obesity in male mice.

Women are drawn to MOTS-c for several reasons. Mitochondrial decline, insulin resistance, and abdominal fat redistribution all accelerate during perimenopause, the hormonal transition that can begin as early as the mid-30s and extend into the early 50s. Research published in the Journal of Clinical Endocrinology and Metabolism has shown that ovarian hormone withdrawal directly reduces mitochondrial biogenesis in skeletal muscle, which is precisely the tissue MOTS-c appears to target. Women with PCOS also present with measurable mitochondrial dysfunction and elevated oxidative stress, making MOTS-c a conceptually attractive option even though no PCOS-specific trials exist yet.

The honest caveat: the vast majority of mechanistic and pre-clinical work was done in male animals or male-predominant human samples. Until adequately powered trials enroll women across reproductive stages, any clinical use in women is extrapolation. Your clinician should document that clearly.

The Coverage Reality in 2026

Why Standard Insurance Does Not Cover MOTS-c

MOTS-c has no FDA new drug application, no approved indication, and no CPT billing code. Most commercial health plans explicitly exclude compounded drugs that have no FDA-approved reference product, and MOTS-c falls into that category. Medicare and Medicaid coverage is not available. Even plans that cover other compounded peptides (such as compounded semaglutide, which occupied its own regulatory gray zone before the FDA shortage designation was resolved) are unlikely to extend coverage to MOTS-c.

What ICHRA Is and How It Could Help

An Individual Coverage Health Reimbursement Arrangement (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, depending on plan design, qualified medical expenses. The IRS finalized ICHRA rules in 26 CFR Part 54 effective January 2020, and employers can customize which expense categories they reimburse beyond premiums.

Here is a practical framework for MOTS-c ICHRA reimbursement, organized by what you can actually control:

Step 1. Confirm your employer offers an ICHRA (not a standard group plan). ICHRA and traditional group health plans are mutually exclusive for the same class of employees. If you are on a group plan, ICHRA does not apply to you.

Step 2. Review your ICHRA plan document for "qualified medical expenses." The IRS defines qualified medical expenses by reference to IRS Publication 502. Compounded prescription drugs dispensed pursuant to a valid prescription are generally qualified medical expenses under Section 213(d). Your plan document may explicitly include or exclude compounded peptides; read it carefully or ask HR for the Summary Plan Description.

Step 3. Get a documented diagnosis and prescription. ICHRA reimbursement for a compounded drug typically requires a valid prescription from a licensed prescriber. A note documenting medical necessity (for example, mitochondrial dysfunction in the context of perimenopausal metabolic decline, insulin resistance, or another ICD-10-coded condition your clinician supports) strengthens your reimbursement claim substantially.

Step 4. Submit itemized receipts from an accredited compounding pharmacy. The pharmacy invoice must show the drug name, dose, quantity, prescribing clinician's name, and your name. PCAB-accredited or 503B compounding facilities are preferred because they carry stronger quality documentation.

Step 5. Keep your Explanation of Benefits if your ICHRA reimburses via insurance. Some ICHRAs only reimburse after insurance processes a claim; because MOTS-c has no coverage pathway, these plans may not be useful. Pure expense-reimbursement ICHRAs are the better vehicle.

ICHRA rules change with annual IRS guidance and employer plan-year renewals. Confirm the current rules with your plan administrator or a benefits attorney before submitting.

HSA and FSA Eligibility for MOTS-c

The Core Rule

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can pay for prescription drugs that treat a specific medical condition. The governing statute is IRC Section 213(d). A compounded drug dispensed under a valid prescription for a diagnosed condition qualifies as a medical expense. A peptide purchased without a prescription for general wellness does not.

What You Need to Qualify

• A licensed prescriber (MD, DO, NP, or PA operating within scope) who writes a prescription for MOTS-c and documents a clinical rationale.
• An ICD-10 diagnosis code your clinician is comfortable supporting. Possible codes include E11.65 (type 2 diabetes with hyperglycemia), E88.89 (other specified metabolic disorders), or N95.1 (menopausal and female climacteric states) depending on your clinical picture.
• A pharmacy receipt showing the drug name, dose, and prescription number.

HSA vs. FSA Nuances for Women

If you are of reproductive age and using an HSA paired with a High Deductible Health Plan (HDHP), your HSA funds carry over year to year, which makes them a good vehicle for ongoing peptide therapy costs. If you use an FSA, the use-it-or-lose-it rule (with limited grace periods) means you should time your spending to your FSA plan year.

Women on Marketplace plans who receive premium tax credits must use an ICHRA or a qualifying HDHP to open an HSA. Your telehealth prescriber can confirm whether your insurance arrangement is HDHP-compatible.

Employer Wellness Stipends and Lifestyle Spending Accounts

An increasing number of employers, particularly in tech and healthcare sectors, offer Lifestyle Spending Accounts (LSAs) or wellness stipends that are separate from ICHRA and FSA/HSA. These are taxable employer benefits (unlike HSA/FSA contributions, which are pre-tax), but they can cover items outside the IRS Section 213(d) definition, including some wellness-oriented compounded peptides.

Because LSAs are taxable to the employee, you will owe ordinary income tax on reimbursements. Still, if your employer offers $1,000/year in LSA funds and your MOTS-c cost is $200/month, an LSA can absorb two or three months of expense.

Ask HR whether your wellness stipend explicitly includes compounded prescription drugs or peptides, and whether a prescription is required.

How to Get MOTS-c at a Lower Cost: Direct Strategies

Choose a 503A Compounding Pharmacy With Transparent Pricing

MOTS-c is currently dispensed by 503A compounding pharmacies (patient-specific prescriptions) and, in limited cases, 503B outsourcing facilities (for office use). Pricing varies widely because MOTS-c raw peptide cost and quality controls differ across suppliers. A 30-day supply of subcutaneous MOTS-c at a common starting dose (5 mg, three times per week) ranges from approximately $150 to $400 depending on the pharmacy.

Strategies to lower pharmacy cost:

• Ask whether the pharmacy offers a multi-month supply discount. Some compound pharmacies reduce per-unit cost by 10-15% for 90-day supplies.
• Confirm PCAB accreditation or USP 797/800 compliance. Cheaper is not always safer for sterile injectables.
• Ask your prescriber whether the pharmacy participates in any patient-assistance or loyalty programs.

Telehealth Prescribers and Bundled Programs

Some telehealth platforms bundle the consultation fee and pharmacy dispensing fee, which lowers the effective cost compared to paying separately. WomanRx's clinical team can review your metabolic and hormonal labs and write a prescription if MOTS-c is clinically appropriate for your situation.

Membership and Subscription Models

A small number of direct-primary-care or functional-medicine practices offer membership models where the monthly fee covers unlimited clinician access and discounted compounding pharmacy orders. If you are already paying for this type of membership for another service (such as GLP-1 management or hormone therapy), ask whether MOTS-c is included.

Sex-Specific Physiology: What the Data Actually Shows in Women

Menstrual Cycle and Mitochondrial Function

Mitochondrial activity in women is not static across the menstrual cycle. Estrogen, particularly 17-beta-estradiol, upregulates mitochondrial biogenesis through estrogen receptor beta signaling in skeletal muscle. A 2019 review in Frontiers in Physiology documented that estradiol enhances oxidative phosphorylation capacity and antioxidant enzyme expression in muscle. Because MOTS-c acts on similar mitochondrial pathways, there is theoretical overlap, but no trial has examined whether MOTS-c pharmacodynamics differ across menstrual cycle phases in women.

Perimenopause and Postmenopause

The decline in estradiol during perimenopause is associated with reduced mitochondrial efficiency, increased reactive oxygen species production, and accelerated insulin resistance. These are the same metabolic targets MOTS-c appears to address in pre-clinical models. A 2021 paper in Nature Metabolism showed that circulating MOTS-c levels in humans decline with age and correlate with insulin sensitivity, though this was a mixed-sex cohort and sex-stratified data were not reported separately.

If you are perimenopausal or postmenopausal and already on menopausal hormone therapy (MHT), ask your clinician whether MOTS-c is additive, redundant, or potentially interacting with your estrogen regimen. No interaction data exist; this is a genuine evidence gap.

PCOS

Women with PCOS have documented mitochondrial dysfunction in granulosa cells and skeletal muscle, alongside elevated androgen levels and insulin resistance. A 2020 study in the Journal of Clinical Endocrinology and Metabolism confirmed that mitochondrial electron transport chain activity is reduced in PCOS skeletal muscle compared to matched controls. MOTS-c has not been studied in PCOS patients. Any use in this population is extrapolation from mechanism, not from trial data.

Trying to Conceive and Reproductive-Age Women

If you are trying to conceive, the absence of safety data in pregnancy is disqualifying. Stop MOTS-c before attempting pregnancy. Discuss the timing with your reproductive endocrinologist.

Pregnancy, Lactation, and Contraception: Required Safety Information

MOTS-c is not studied in human pregnancy and should be considered contraindicated until proven otherwise.

There is no FDA pregnancy category because MOTS-c is not an approved drug. No animal reproductive toxicology studies have been published in peer-reviewed form. No human pregnancy exposure data exist in published literature as of January 2026.

The ACOG general principle on investigational agents in pregnancy is that unapproved drugs with no reproductive safety profile should not be used in pregnancy unless a formal clinical trial with appropriate consent and oversight is in place. MOTS-c does not meet that threshold.

Lactation: No data on MOTS-c transfer into human breast milk exist. Given the peptide's molecular weight (approximately 2.1 kDa) and its route of administration (subcutaneous injection), some systemic absorption and theoretical milk transfer is plausible. Without data, use during lactation is not advised.

Contraception requirement: Women of reproductive age who use MOTS-c should use reliable contraception throughout treatment. If you are planning a pregnancy, discontinue MOTS-c at least one full menstrual cycle before attempting conception, and inform your OB-GYN of prior use.

Postmenopausal women do not require contraception for MOTS-c specifically, but should still disclose use to their clinician given the absence of long-term safety data.

Who This Is Right For and Who Should Wait

Women Who May Be Appropriate Candidates

• Perimenopausal or postmenopausal women with documented insulin resistance or metabolic syndrome who have not responded adequately to lifestyle modification and are not candidates for or are declining GLP-1 agonists.
• Women with PCOS and mitochondrial-pattern metabolic dysfunction, after discussion with a reproductive endocrinologist.
• Women in their reproductive years who are on reliable contraception, understand the investigational nature of the therapy, and are working with a clinician who documents a specific clinical rationale.

Women Who Should Not Use MOTS-c

• Pregnant women or those planning pregnancy in the near term.
• Breastfeeding women.
• Women who want a treatment with an established FDA safety and efficacy profile. MOTS-c does not offer that.
• Women with active liver disease, autoimmune conditions affecting mitochondrial function, or concurrent use of drugs with unknown mitochondrial interactions, until more data are available.

Tracking Your Response: What to Measure

Because MOTS-c has no validated biomarker panel for clinical monitoring, your prescriber should agree in advance on what "response" means for you. Reasonable baseline and follow-up labs include:

• Fasting insulin and glucose, with HOMA-IR calculation.
• HbA1c (if metabolic indication).
• FSH, LH, estradiol (if perimenopausal, to contextualize mitochondrial symptoms).
• AMH (if reproductive-age and cycle irregularity is part of the clinical picture).
• Comprehensive metabolic panel to monitor liver and kidney function.
• Fasting lipid panel, given MOTS-c's proposed role in lipid metabolism from a 2021 study in Cell Reports.

Reassess at 8-12 weeks. If no measurable change in primary metabolic markers occurs, the risk-benefit ratio of continuing an unapproved therapy shifts.

A Note on the Evidence Gap

Women have been historically underrepresented in peptide and metabolic research. The original MOTS-c mouse studies used male animals exclusively. The 2015 Cell Metabolism paper by Lee et al. Did not report sex-stratified outcomes in the human genetic association data it included. The 2021 Nature Metabolism aging study included women but did not report MOTS-c levels by sex or menstrual status separately.

This matters for your clinical decision. Any dose, frequency, or effect estimate you read about MOTS-c is derived largely from male biology. Your clinician is extrapolating. That extrapolation may be reasonable given mechanism, but it should be named clearly, documented in your chart, and revisited as new data emerge.